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Abstract: Cerebral Venous Sinus (sinovenous) 
increasingly recognized and diagnosed in pediatric patients. The etiology and pathophisiology has 
not  yet  been  completely  clarified,  and  unlike  adults  with  CSVT,  management  in  children  and 
neonates remains controversial. However, morbidit
continued need for high-quality studies within this field. The following review will highlight aspects 
of CSVT in the mediteranian area in children.
 
Epidemiology:  The  incidence  of  childhood  CSVT 
varies between  0.4 and 0.7  per 100,000 children  per 
year.
1-3  More  than  40%  of  childhood  CSVT  occurs 
within the neonatal period, with an incidence of 2.6 per 
100,000 children per year in one series.
1 Notably, these 
reported figures are probably underestimates of the true 
rate of CSVT occurrence, since neonates often present 
with  nonfocal  neurologic  signs  and  symptoms, 
potentialy leading to missed  diagnosis.
2 
techniques,  the  variable  anatomy  of  sinovenous 
channels and rapid recanalization are all factors which 
may  contribute  to  underdiagnosis.
4 
incidence of sinus vein thrombosis among children in 
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inus (sinovenous) Thrombosis (CSVT) is a serious an
increasingly recognized and diagnosed in pediatric patients. The etiology and pathophisiology has 
not  yet  been  completely  clarified,  and  unlike  adults  with  CSVT,  management  in  children  and 
neonates remains controversial. However, morbidity and mortality are significant, highlighting the 
quality studies within this field. The following review will highlight aspects 
of CSVT in the mediteranian area in children. 
The  incidence  of  childhood  CSVT 
varies between  0.4 and  0.7 per  100,000  children per 
More  than  40%  of  childhood  CSVT  occurs 
within the neonatal period, with an incidence of 2.6 per 
Notably, these 
reported figures are probably underestimates of the true 
rate of CSVT occurrence, since neonates often present 
with  nonfocal  neurologic  signs  and  symptoms, 
 Old imaging 
,  the  variable  anatomy  of  sinovenous 
channels and rapid recanalization are all factors which 
  The  annual 
incidence of sinus vein thrombosis among children in 
the  mediteranian  area  is  not  reported.  Some  case
series,  cohort and case controlled multicenter studies 
are  available  from  Lebanon,  Turkey,  France,  Italy, 
Portugal  and  Israel.
5-10  CSVT  incidence  evaluated 
among children and neonates hospitalized in a tertiary 
medical  center  in  Israel  was  as  high  as  2/10,000
potentially  due  to  selection  bias,  in  a  referral  center 
with  high  clinical  awareness  and  high  index  of 
suspicion  that  led  towards  early  diagnosis  and 
treatment  of  CSVT.  The  largest  European  CSVT 
cohort consisted of 396 children , prospectively studied 
and  followed  in  order  to  asses  the  risk  factors 
associated with thrombosis recurrence.
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hrombosis (CSVT) is a serious and rare disorder,  
increasingly recognized and diagnosed in pediatric patients. The etiology and pathophisiology has 
not  yet  been  completely  clarified,  and  unlike  adults  with  CSVT,  management  in  children  and 
y and mortality are significant, highlighting the 
quality studies within this field. The following review will highlight aspects 
the  mediteranian  area  is  not  reported.  Some  case- 
and case  controlled multicenter studies 
are  available  from  Lebanon,  Turkey,  France,  Italy, 
CSVT  incidence  evaluated 
among children and neonates hospitalized in a tertiary 
medical  center  in  Israel  was  as  high  as  2/10,000,
11 
ally  due  to  selection  bias,  in  a  referral  center 
with  high  clinical  awareness  and  high  index  of 
suspicion  that  led  towards  early  diagnosis  and 
treatment  of  CSVT.  The  largest  European  CSVT 
cohort consisted of 396 children , prospectively studied 
d  in  order  to  asses  the  risk  factors 
associated with thrombosis recurrence.
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Anatomy  and  Pathophysiology:  Cerebral  vascular 
malformations  may  involve  the  venous  circulation, 
with “developmental venous anomaly” ( DVA) being 
the most frequent. This term, proposed by Lasjaunias et 
al.,
13  is  now  widely  used  as  a  synonym  for  venous 
angioma,  cerebral  venous  malformation,  or  cerebral 
venous  medullary  malformation.  DVAs  are 
encountered    with  an  incidence  of  up  to  2.6%  in  a 
series  of  4,069  brain  autopsies.
14  They  represent  an 
anomalous  venous  disposition  due  to  the  absence  of 
normal  pial  or  subependymal  veins. They may  drain 
into both the superficial and deep venous systems, and 
a stenosis of the collecting vein of DVAs is commonly 
observed, typically at the point where the vein crosses 
the dura to drain into a dural venous sinus.  The most 
frequently  involved  sites  of  CSVT  are  the  superior 
sagittal sinus (90% of all cases in most studies) and 
transverse sinuses of the superficial venous system and 
the straight sinus of the deep system.
15 After CSVT, 
venous pressure escalates in the occluded vessels and 
secondary  hemorrhagic  infarction  develops  due  to 
brain tissue hypertension, localized venous congestion, 
vasogenic  edema, and  increased capillary  hydrostatic 
pressure  in  excess  of  cerebral  arteriolar  blood  flow. 
Approximately 65% of neonates with CSVT have brain 
parenchymal lesions, frequently detected in the frontal 
and parietal lobes.
16 
 
Clinical Presentation and Symptoms: It is apparent 
that  the  clinical  manifestations  of  CSVT  are  non-
specific and may be subtle. Clinical scenarios occur at 
all ages and the clinician should consider this diagnosis 
in a wide range of acute neurological presentations in 
childhood.  These  include  seizures,  coma,  stroke, 
headache  and  increased  intracranial  pressure.
17 
Common  illnesses,  eg:  ear  infections,  meningitis, 
anaemia, diabetes and head injury, may lead to CSVT 
evolution,  various  clinical  settings  including  sepsis, 
dehydration,  renal  failure,  trauma,  cancer  and 
haematological  disorders  may  precipitate.
18  Although 
presentation with pseudotumour cerebri has been well 
documented, there are few data on the prevalence of 
CSVT  in  otherwise  unexplained  hydrocephalus  or  in 
convulsive  and  non-convulsive  seizures  and  status 
epilepticus.
19  It  has  been  suggested  that  toddlers 
frequently present with seizures and focal signs, mainly 
hemiparesis,  whereas  older  children  present  with 
headache  and  changes  in  mental  status  and  seizures 
may  be less common.
20  In  a  study  of  neonatal sinus 
vein thrombosis (52 neonates with a median gestational 
age  of  39  weeks),  symptoms  developed  at  a  median 
postnatal  age  of  1.5  days  (range:  0  to  28  days)  and 
consisted  mainly  of  seizures  (29  of  52).
21  Other 
presenting  findings  in  neonates  were  apnea  (17.3%), 
agitation  (5.8%),  sepsis  like(3.8%)  and  decreased 
consciousness  in  up to 2%.
22  The  majority  of young 
children present acutely with seizures, focal signs and 
symptoms  of  raised  intracranial  pressure,  such  as 
headache  and  decreased  level  of  consciousness. 
Subacute  presentation,  with  chronic  headache, 
vomiting, lethargy, anorexia or drowsiness for 3 weeks 
or more, may also occur.
23 
 
Diagnosis  and  Imaging  Studies:  The  clinical 
spectrum  of  CVST closely mimics  that  of idiopathic 
intracranial  hypertension.  Ultrasonography,  which  is 
the  preliminary  screening  test  for  hemorrhage  in  the 
neonatal period, may detect intraventricular bleeding, 
centrally located venous infarcts or hemorrhages, and 
ventricular  dilation  and  leukomalacia  secondary  to 
CSVT  infarction  and  ischemia.  However,  ultrasound 
has poor sensitivity for cerebral infarction and should 
not be used for the primary detection of CSVT and the 
extent  of  ensuing  injury.
24,25  Cranial  computed 
tomography (CT) can be performed rapidly in neonates 
with minimum sedation but misses CSVT in 15% of 
cases. The classic features that indicate CSVT include 
the “dense triangle” or the “cord sign,” which describe 
the increased density over the thrombosed venous sinus 
in  a  plain  CT,  or  the“empty  triangle”[].
26  A 
communicating hydrocephalus may be associated with 
sagittal sinus thrombosis caused by the impaired CSF 
absorption over the arachnoid granulations that line the 
sagittal  sinus.  A  CT  venogram  using  the  multislice 
technique    is  more  sensitive  and  specific  for  the 
diagnosis  of  CSVT,  but  the  consequent  radiation 
exposure is a definite concern in neonates. MRI is free 
of radiation risk and permits earlier and more accurate 
detection of CSVT.
27 Diffusion-weighted imaging is a 
sensitive  technique  for  detecting  areas  of  infarction. 
Parenchymal  changes  can  be  seen  within  minutes  of 
injury,  which  allows  for  early  identification  and 
intervention  and  Magnetic  resonance  venography 
allows  for  noninvasive  assessment  of  the  venous 
system without exposure to radiograph radiation. Using 
time-offlight  techniques,  the  cerebral  sinuses  can  be 
imaged  even  without  the  use  of  contrast.  Currently, 
contrast-enhanced  magnetic  resonance  venography, 
which is less susceptible to alterations in flow, is the 
imaging technique of choice for the detection of CSVT 
in  the  neonatal  population.
28  Attached  are  2 
representative  MR  figures  of  CSVT  in  pediatric 
patients (Figures 1,2). 
 
Etiology  and  risk  factors:  The  etiology  and 
pathophysiology of CSVT in the pediatric population is 
still poorly understood, and the role of thrombophilic Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure  1:  Cranial  MRI-  demonstrating  occlusion  of  the  sagittal 
sinus thrombosis. 
 
Figure  2:  Cranial  MRV-  demonstrating  occlusion  of  the  left 
transverse and sigmoid sinuses. 
 
risk  factors  remains  to  be  elucidated.
Trauma, infections (especially sinusitis, mastoiditis and 
other  conditions  affecting  the  head  and  neck  area)  , 
collagen  vascular  disorders,  hemoglobinopathies, 
metabolic  and  inflamatory  bowel  diseases  have  been 
suggested  as  potential  risk  factors  for  CSVT 
occurrence in small cohort and case study  series.
Several case-control studies have dealth with the role 
of prothrombotic risk factors in the pathphysiology of 
CSVT.
1-5,10-12,39-44 In a recent meta- analysis of pediatric 
case-  controlled  studies  thrombophilia  certainly 
increased the risk of  stroke or CSVT in patients aged 
0-18  years  old,  especially  when  combination  of 
thrombophilic  risk  factors  was  diagnosed.
statistically  significant  association  with  first    event 
: Open Journal System 
 
demonstrating  occlusion  of  the  sagittal 
 
demonstrating  occlusion  of  the  left 
risk  factors  remains  to  be  elucidated.
1-5,10-12,29-30 
Trauma, infections (especially sinusitis, mastoiditis and 
other  conditions  affecting  the  head  and  neck  area)  , 
collagen  vascular  disorders,  hemoglobinopathies, 
bowel  diseases  have  been 
suggested  as  potential  risk  factors  for  CSVT 
occurrence in small cohort and case study series.
31-38 
control studies have dealth with the role 
of prothrombotic risk factors in the pathphysiology of 
analysis of pediatric 
controlled  studies  thrombophilia  certainly 
increased the risk of  stroke or CSVT in patients aged 
18  years  old,  especially  when  combination  of 
thrombophilic  risk  factors  was  diagnosed.
45  A 
ificant  association  with  first    event 
occurrence  was  demonstrated  for  each  thrombophilia 
trait  evaluated,  with  no  difference  found  between 
arterial  ischemic  stroke  and  CSVT.  Summary  ORs 
(fixed-effects  model)  were  as  follows:  antithrombin 
deficiency,  7.06  (95%  CI,  2.44  to  22.42);  protein  C 
deficiency,  8.76  (95%  CI,  4.53  to  16.96);  protein  S 
deficiency,  3.20  (95%  CI,  1.22  to  8.40),  factor  V 
G1691A,  3.26  (95%  CI,  2.59  to  4.10);  factor  II 
G20210A,  2.43  (95%  CI,  1.67  to  3.51);  MTHFR 
C677T  (AIS),  1.58  (95%  CI,  1.
antiphospholipid antibodies (AIS), 6.95 (95% CI, 3.67 
to 13.14); elevated lipoprotein(a), 6.27 (95% CI, 4.52 
to 8.69), and combined thrombophilias, 11.86 (95% CI, 
5.93 to 23.73). Genetic thrombophilia, and especially 
presence  of  prothrombin  G2
significantly  increase  the  risk  of  recurrent 
thromboembolism in CSVT patients older than 2 years 
of  age,
12  in  situations  of  future  acquired 
hypercoagulability. 
 
Outcome:  Over  all  neonates  have  a  more  favorable 
outcome as compared to older children.
in  the  majority  of  studies  the  authors  did  not 
adequately  describe  outcomes  in  neonates  compared 
with those of children with CSVT. The mean age of 
follow-up  varied  across  the  studies,  and  disabilities 
were  variably  classified.
47  Cur
substantial  differences  in  reporting  the  correct 
neurodevelopment  outcome  of  neonates  and  children 
with  CSVT,  mainly  due  to  lack  of  standardized 
assesment  protocols.  Neurologic  deficits  including 
epilepsy, motor impairments, and a range o
impairments  were  reported  for  10%  to  80%  of  all 
neonates  on  follow  up.  Wasay  et  al[]
higher  mortality  rate  from  CSVT  in  neonates, 
significantly  associated  with  coma  and  seizures 
occuring  at  presentation.  Other  predictors  of  poor 
neurologic  outcome  were  coagulation  abnormalities, 
multiple sinus thrombosis, seizures at presentation, and 
venous  infarction.
49-50  Notably,  CSVT  prognosis  was 
found to be better when compared to arterial ischemic 
stroke.
51-52 Nearly 50% of CSVT patients do 
infarcts  and  may  suffer  fewer  motor  deficits  or  no 
permanent damage.
53 
 
Therapy:  There  are  no  evidence  based 
recommendations  for  the  therapy  of  thrombosis  in 
children  due  to  the  lack  of  randomized  controlled 
trials.
54 The aim of antithrombotic therapy after CSVT 
is vascular patency, mitigation of thrombus growth and 
the  avoidance  of  a  new  thrombosis  in  the  phase  of 
secondary prophylaxis after the acute treatment period. 
Therapy outcome in children differs. This is in pa
to the absence of controlled trials with comparable end 
points. Although not treating CSVT may significantly 
 
occurrence  was  demonstrated  for  each  thrombophilia 
trait  evaluated,  with  no  difference  found  between 
arterial  ischemic  stroke  and  CSVT.  Summary  ORs 
effects  model)  were  as  follows:  antithrombin 
95%  CI,  2.44  to  22.42);  protein  C 
deficiency,  8.76  (95%  CI,  4.53  to  16.96);  protein  S 
deficiency,  3.20  (95%  CI,  1.22  to  8.40),  factor  V 
G1691A,  3.26  (95%  CI,  2.59  to  4.10);  factor  II 
G20210A,  2.43  (95%  CI,  1.67  to  3.51);  MTHFR 
C677T  (AIS),  1.58  (95%  CI,  1.20  to  2.08); 
antiphospholipid antibodies (AIS), 6.95 (95% CI, 3.67 
to 13.14); elevated lipoprotein(a), 6.27 (95% CI, 4.52 
to 8.69), and combined thrombophilias, 11.86 (95% CI, 
5.93 to 23.73). Genetic thrombophilia, and especially 
presence  of  prothrombin  G20210A  mutation 
significantly  increase  the  risk  of  recurrent 
thromboembolism in CSVT patients older than 2 years 
in  situations  of  future  acquired 
Over  all  neonates  have  a  more  favorable 
ildren.
46 Nevertheless, 
in  the  majority  of  studies  the  authors  did  not 
adequately  describe  outcomes  in  neonates  compared 
with those of children with CSVT. The mean age of 
up  varied  across  the  studies,  and  disabilities 
Curently,  there  is  a 
substantial  differences  in  reporting  the  correct 
neurodevelopment  outcome  of  neonates  and  children 
with  CSVT,  mainly  due  to  lack  of  standardized 
assesment  protocols.  Neurologic  deficits  including 
epilepsy, motor impairments, and a range of cognitive 
impairments  were  reported  for  10%  to  80%  of  all 
neonates  on  follow  up.  Wasay  et  al[]
48  reported  a 
higher  mortality  rate  from  CSVT  in  neonates, 
significantly  associated  with  coma  and  seizures 
occuring  at  presentation.  Other  predictors  of  poor 
urologic  outcome  were  coagulation  abnormalities, 
multiple sinus thrombosis, seizures at presentation, and 
Notably,  CSVT  prognosis  was 
found to be better when compared to arterial ischemic 
Nearly 50% of CSVT patients do not have 
infarcts  and  may  suffer  fewer  motor  deficits  or  no 
There  are  no  evidence  based 
recommendations  for  the  therapy  of  thrombosis  in 
children  due  to  the  lack  of  randomized  controlled 
The aim of antithrombotic therapy after CSVT 
is vascular patency, mitigation of thrombus growth and 
the  avoidance  of  a  new  thrombosis  in  the  phase  of 
secondary prophylaxis after the acute treatment period. 
Therapy outcome in children differs. This is in part due 
to the absence of controlled trials with comparable end 
points. Although not treating CSVT may significantly Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
increase  the  risk  of  thrombus  propagation  that  is 
associated  with  new  venous  infarctions  and  worse 
clinical outcomes, safety issues should be considered. 
Whereas in adults anticoagulant therapy of CSVT is 
recommended,
55 such therapy is currently less obvious 
for  children  and  neonates.
56  A  recent  multi-center 
Portuguese  study  reported  no  influence  of 
anticoagulation upon CSVT outcome.
57 However, in a 
single center pediatric CSVT cohort, Mahendranath et. 
al describe a rate of 6% treatment related hemorrhage 
and a  31% rate of thrombus propagation in untreated 
patients.
58 
Notably,  prospective  follow  up  of  the  European 
pediatric CSVT cohort reflected the need for secondary 
anticoagulant prophylaxis in future high risk situations, 
especially in children with thrombophilia and lack of 
thrombus  recanalization  following  acute  phase 
therapy.
12  Pediatric  hematology  expert  groups 
recommend  tailored  therapy  regimens  based  upon 
patient’s  condition,  combinations  of  risk  factors  and 
presumed recurrence risk.
59-61 
Thrombolytic therapy is generally limited to severe 
cases with a high risk of mortality.
62-64 
Generally,  disease  severity  would  be  associated 
with  antithrombotic  treatment,  especially  in  non- 
neonates. Markers of severity may include presentation 
with  diffuse  signs/  massive  extended  thrombosis  or 
altered  level  of  consciousness.  Children  with 
congenital  or  acquired  heart  disease  require 
heparinization. The presence of thrombophilia and lack 
of  transient  risk  factors  (namely:  idiopathic  CSVT) 
determines  the  need  for  prolonged  anticoagulant 
therapy. 
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